Quick Take
Inhibikase Therapeutics (IKT) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases.
IKT is still at a preclinical stage of development, is thinly capitalized and the IPO may be more suited to long-term hold institutional investors.
Company & Technology
Atlanta, Georgia-based Inhibikase was founded to develop small molecule inhibitory drugs to treat Parkinson's Disease, cancer and other conditions.
Management is headed by founder, president